CompletedPHASE1, PHASE2NCT03415594
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
Studying Chronic intestinal failure
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GlyPharma Therapeutics
- Principal Investigator
- Tomasz MasiorVectivBio AG
- Intervention
- FE203799 GLP-2 analogue(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- Rigshospitalet, Copenhagen, Denmark
Collaborators
VectivBio AG
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03415594 on ClinicalTrials.govOther trials for Chronic intestinal failure
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06777251Changing the Future of Intestinal Failure in Intestinal Chronic Inflammation (INT-FAIL)Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT07422792Anabolic Response To Intravenous Amino Acids In Chronic Intestinal Failure PatientsInstitute of Oncology Ljubljana
- RECRUITINGNCT04629014Prospective Multisite Study of Quality of Life in Pediatric Intestinal FailureBoston Children's Hospital